TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9497790

Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (28.9 +/- 2.1 mu-units/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (101.7 +/- 6.8 mu-units/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 0
Study: 8212753

Group type: EXPERIMENTAL
Intervention: lopamidol (Solutrast 300)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Meglumine iothalamate (Conray 60)
Number of subjects: 63
Study: 3092712

Group type: EXPERIMENTAL
Intervention: Auranofin (6 mg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: D-penicillamine (250 mg/d for 4 weeks, 500 mg/d for 4 weeks, then 750 mg/d thereafter)
Number of subjects: 90
Study: 30604188

Group type: EXPERIMENTAL
Intervention: Carvedilol (+)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Carvedilol (−)
Number of subjects: 132
Study: 29937346

Group type: EXPERIMENTAL
Intervention: Single-Bundle (SB) ACL Reconstruction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Double-Bundle (DB) ACL Reconstruction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Laxitester measurements for both SB and DB
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Osteoarthritic changes and tunnel widening for both SB and DB
Number of subjects: 64
Study: 27404027

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/d
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study: 24178236

Group type: COMPARATOR
Intervention: Mirabegron OCAS 25-400 mg single doses
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mirabegron OCAS 100-200 mg once daily for 7 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mirabegron OCAS up to 400 mg single doses
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mirabegron OCAS up to 200 mg multiple doses
Number of subjects: 76
Study: 22914520

Group type: EXPERIMENTAL
Intervention: Mid-day nap (up to 20 minutes); Mean sleep duration: 8.4 +/- 3.0 minutes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no nap, engaged in conversation)
Number of subjects: 29
Study: 19209184

Group type: EXPERIMENTAL
Intervention: Hydroxypropylmethylcellulose (HPMC) 2.5 g twice daily for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (placebo) for 4 weeks
Number of subjects: 13
Study: 17618766

Group type: EXPERIMENTAL
Intervention: Posterior colporrhaphy, site-specific repair, site-specific repair with Fortagen graft augmentation (specific intervention details not provided)
Number of subjects: 106
Study: 15180082

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 14

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 14
Study: 11805614

Group type: EXPERIMENTAL
Intervention: Sygen (two doses)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9543170

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (25 mg as an i.v. bolus)
Number of subjects: 30
Study: 7509381

Group type: EXPERIMENTAL
Intervention: MOPP/ABVD
Number of subjects: 207

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 207
Study: 2971744

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31628863

Group type: EXPERIMENTAL
Intervention: Silicone dressings applied to sacrum and heels
Number of subjects: 475

Group type: COMPARATOR
Intervention: No dressings (control group)
Number of subjects: 475
Study: 29337134

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 27421546

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No General Anesthesia (non-GA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no IAT)
Number of subjects: 0
Study: 25602901

Group type: EXPERIMENTAL
Intervention: Buckle‐Up Safely program
Number of subjects: 830
Study: 23456697

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study: 21917254

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 18162660

Group type: EXPERIMENTAL
Intervention: Group-based pride in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-based sympathy in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pride in Study 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sympathy in Study 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guilt in all studies
Number of subjects: 0
Study: 17056948

Group type: COMPARATOR
Intervention: saline IV (control)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg IV
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg IV
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: combination of droperidol 1.25 mg and ondansetron 4 mg IV
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ondansetron, droperidol, or their combination
Number of subjects: 400
Study: 11932585

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte (CHO) drinks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P) drinks
Number of subjects: 10
Study: 10077192

Group type: EXPERIMENTAL
Intervention: Penicillin G (1-day regimen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (5-day regimen)
Number of subjects: 30
Study: 7743614

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study: 2258346

Group type: EXPERIMENTAL
Intervention: Pefloxacin plus metronidazole
Number of subjects: 271

Group type: COMPARATOR
Intervention: Gentamicin plus metronidazole
Number of subjects: 271
Study: 7028532

Group type: EXPERIMENTAL
Intervention: Diclofensine (50 mg daily, titrated up to 150 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Maprotiline (reference drug)
Number of subjects: 27
Study: 31112652

Group type: EXPERIMENTAL
Intervention: Phonomotor treatment
Number of subjects: 25
Study: 28427084

Group type: EXPERIMENTAL
Intervention: Adapted physical activity and nutritional education (APANE)
Number of subjects: 251
Study: 26049702

Group type: EXPERIMENTAL
Intervention: Molecular imaging as a biomarker for targeted cancer therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging tests integrated in therapeutic clinical trials
Number of subjects: 0
Study: 23400602

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels in TODAY youth
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous activity levels in TODAY youth
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels in TODAY girls
Number of subjects: 699
Study: 21177785

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (D3) at 50,000 IU/wk for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Vitamin D2 (D2) at 50,000 IU/wk for 12 weeks
Number of subjects: 33
Study: 19665275

Group type: EXPERIMENTAL
Intervention: 0.1% polyoxyethylene (10) octylphenyl ether with MB solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0% polyoxyethylene (10) octylphenyl ether with MB solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: MB solution only
Number of subjects: 0
Study: 17765762

Group type: EXPERIMENTAL
Intervention: LigaSure Vessel Sealing System tonsillectomy (LT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel tonsillectomy (HST)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cold knife tonsillectomy (CKT)
Number of subjects: 161
Study: 15208517

Group type: EXPERIMENTAL
Intervention: Management development programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study: 11525552

Group type: EXPERIMENTAL
Intervention: Microwave disinfection system for soft contact lenses (used by 56 subjects for 1 month)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (not specified how many subjects)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Microwave disinfection system for soft contact lenses (used by 13 subjects for 3 months)
Number of subjects: 103
Study: 9271481

Group type: EXPERIMENTAL
Intervention: Hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Simvastatin (10 mg daily)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 58
Study: 8511810

Group type: EXPERIMENTAL
Intervention: Proguanil (PROG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine-Proguanil combination (CQ+PROG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 3596882

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 31237187

Group type: EXPERIMENTAL
Intervention: Severe ASM (≥400 μm of maximum malapposed distance)
Number of subjects: 436

Group type: COMPARATOR
Intervention: No ASM or ASM <400 μm of maximum malapposed distance
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Severe ASM (≥1 mm of maximum malapposed length)
Number of subjects: 436

Group type: COMPARATOR
Intervention: No ASM or ASM <1 mm of maximum malapposed length
Number of subjects: 436
Study: 28405705

Group type: EXPERIMENTAL
Intervention: Degarelix (GnRH antagonist)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Leuprolide (GnRH agonist)
Number of subjects: 6
Study: 26068298

Group type: EXPERIMENTAL
Intervention: Baumgartner definition (low lean mass alone)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Cruz‐Jentoft definition (low lean mass plus decreased functional performance)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Delmonico 1 definition
Number of subjects: 445

Group type: COMPARATOR
Intervention: Fielding definition
Number of subjects: 445

Group type: COMPARATOR
Intervention: Morley definition
Number of subjects: 445
Study: 23507721

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 16
Study: 21596251

Group type: EXPERIMENTAL
Intervention: Besifloxacin 0.6% ophthalmic suspension
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 105
Study: 20145786

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate injections after knee arthroscopy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Arthroscopy alone
Number of subjects: 46
Study: 16768551

Group type: EXPERIMENTAL
Intervention: suppression condition
Number of subjects: 205

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: distraction condition
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: sensory focus condition
Number of subjects: 205
Study: 15076173

Group type: EXPERIMENTAL
Intervention: Perindopril (plus indapamide if not contraindicated)
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 10699768

Group type: EXPERIMENTAL
Intervention: Reusable biopsy forceps
Number of subjects: 7740

Group type: COMPARATOR
Intervention: Disposable biopsy forceps
Number of subjects: 7740
Study: 9086985

Group type: EXPERIMENTAL
Intervention: Shared medical record access
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational materials only (Control)
Number of subjects: 0
Study: 8450081

Group type: EXPERIMENTAL
Intervention: Metronidazole 200 mg x 3 x 10 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg x 4 x 12 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 27
Study: 3096763

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg daily for four weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2974306

Group type: EXPERIMENTAL
Intervention: Acitretin (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Etretinate (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 31916391

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound transbronchial lung biopsy with rapid on-site evaluation (EBUS-GS-TBLB + ROSE)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Endobronchial ultrasound transbronchial lung biopsy without rapid on-site evaluation (EBUS-GS-TBLB without ROSE)
Number of subjects: 138
Study: 31362530

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12156
Study: 28941589

Group type: EXPERIMENTAL
Intervention: Dexamethasone (12 mg intravenous before chemoembolization)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 88
Study: 26671340

Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare) model
Number of subjects: 675

Group type: COMPARATOR
Intervention: Standard NICU care
Number of subjects: 675
Study: 24097280

Group type: EXPERIMENTAL
Intervention: TRT+TENS
Number of subjects: 30

Group type: COMPARATOR
Intervention: TRT+PLBO
Number of subjects: 30
Study: 22916513

Group type: EXPERIMENTAL
Intervention: Ultrasound technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 120
Study: 20037525

Group type: EXPERIMENTAL
Intervention: Rectal suppository (50 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tablet (50 mg)
Number of subjects: 80
Study: 16390864

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sex steroids
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: GH + sex steroids
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: GH + testosterone
Number of subjects: 124

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 124
Study: 15214586

Group type: EXPERIMENTAL
Intervention: tibolone 1.25 mg/day
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg/day
Number of subjects: 162

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 162
Study: 11126502

Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine
Number of subjects: 30
Study: 9333514

Group type: EXPERIMENTAL
Intervention: Consupren (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide (K)
Number of subjects: 0
Study: 8475234

Group type: EXPERIMENTAL
Intervention: Self-disclosure condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nondisclosure condition
Number of subjects: 60
Study: 3536489

Group type: EXPERIMENTAL
Intervention: Cyclizine, 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perphenazine, 2.5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30730798

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (without VR distraction)
Number of subjects: 120
Study: 28185407

Group type: COMPARATOR
Intervention: Dialysate temperature at 37°C and sodium concentration at 138 mmol/L (Mode A)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Dialysate temperature at 35°C and sodium concentration at 138 mmol/L (Mode B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35°C and sodium concentration changing from 150 mmol/L to 138 mmol/L (Mode C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35°C and sodium concentration changing from 150 mmol/L to 138 mmol/L (Mode D)
Number of subjects: 4
Study: 27422168

Group type: EXPERIMENTAL
Intervention: Yi Jin Jing exercise training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise training
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Yi Jin Jing and Tai Chi exercise training
Number of subjects: 150
Study: 25049330

Group type: EXPERIMENTAL
Intervention: First-line everolimus followed by sunitinib
Number of subjects: 471

Group type: COMPARATOR
Intervention: First-line sunitinib followed by everolimus
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Sequential everolimus then sunitinib
Number of subjects: 471

Group type: COMPARATOR
Intervention: Sequential sunitinib then everolimus
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: First-line everolimus
Number of subjects: 471

Group type: COMPARATOR
Intervention: First-line sunitinib
Number of subjects: 471
Study: 23014091

Group type: EXPERIMENTAL
Intervention: Triple-headed toothbrush
Number of subjects: 4

Group type: COMPARATOR
Intervention: Single-headed toothbrush
Number of subjects: 4
Study: 19651171

Group type: EXPERIMENTAL
Intervention: 100 microg non-adjuvanted RSV-A vaccine
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 100 microg adjuvanted RSV-A vaccine
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 561

Group type: COMPARATOR
Intervention: Alum-placebo
Number of subjects: 561
Study: 17805456

Group type: EXPERIMENTAL
Intervention: Vaginal microbicides
Number of subjects: 708
Study: 15183941

Group type: EXPERIMENTAL
Intervention: Prostatitis patients
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study: 12169777

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study: 9854507

Group type: EXPERIMENTAL
Intervention: Endogenous/exogenous TNF therapy (EET) with recombinant TNF‐SAM2 (rTNF‐S) and anti-cancer drugs (mitomycin-C and 5-FU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Endogenous/exogenous TNF therapy (EET) alone
Number of subjects: 34
Study: 8786726

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2191749

Group type: EXPERIMENTAL
Intervention: One dose of prophylactic antibiotics
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Three doses of prophylactic antibiotics
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 311

Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 311
Study: 517640

Group type: EXPERIMENTAL
Intervention: Compression glove worn during sleep
Number of subjects: 23

Group type: COMPARATOR
Intervention: Loosely fitting glove made of the same material
Number of subjects: 23
Study: 31618430

Group type: EXPERIMENTAL
Intervention: Zinc (25 mg) supplementation
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Vitamin A (2500 IU) supplementation
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Iron (60 mg) supplementation
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study: 31504093

Group type: EXPERIMENTAL
Intervention: Thiamin supplementation (200 mg oral thiamin mononitrate per day for 6 months)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Thiamin supplementation
Number of subjects: 69
Study: 28407050

Group type: EXPERIMENTAL
Intervention: Primary PCI in women
Number of subjects: 2632

Group type: COMPARATOR
Intervention: Primary PCI in men
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Infarct size
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Infarct size as a predictor
Number of subjects: 2632
Study: 26096777

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% and benzoyl peroxide 2.5% gel (A-BPO)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Benzoyl peroxide (BPO)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Dermatological tutorial (DT) for A-BPO application
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-tutorial (NT) for A-BPO application
Number of subjects: 85
Study: 24732290

Group type: EXPERIMENTAL
Intervention: Acetaminophen (OFIRMEV [acetaminophen] injection; Cadence Pharmaceuticals, San Diego, CA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21848172

Group type: EXPERIMENTAL
Intervention: CDI 500 in-line blood gas monitor without gas calibration
Number of subjects: 58

Group type: COMPARATOR
Intervention: CDI 500 in-line blood gas monitor with gas calibration
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CDI 500 in-line blood gas monitor with and without gas calibration after in-vivo calibration
Number of subjects: 58
Study: 19068151

Group type: EXPERIMENTAL
Intervention: Meat enriched in walnut paste (WM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fat meat (LM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Meat enriched in walnut paste (WM) and Low-fat meat (LM)
Number of subjects: 22
Study: 17451889

Group type: EXPERIMENTAL
Intervention: 5-methoxytryptamine (5-MTT) at 1 mg/day orally during light phase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) at 20 mg/day orally during dark phase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5-methoxytryptamine (5-MTT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 100
Study: 15088723

Group type: EXPERIMENTAL
Intervention: FM 2/Diafix‐oral
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 2/MPS gel
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 1/Diafix‐oral
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 1/MPS gel
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 2/MPS gel (ceramic)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 1/MPS gel (ceramic)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 2/Diamond polisher (ceramic)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FM 1/Ceramiste silicon polishers (ceramic)
Number of subjects: 80
Study: 11509778

Group type: EXPERIMENTAL
Intervention: Microlaparoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 20